MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer
- 1 November 2014
- journal article
- Published by Elsevier BV in Cancer Letters
- Vol. 354 (2), 311-319
- https://doi.org/10.1016/j.canlet.2014.08.031
Abstract
No abstract availableKeywords
Funding Information
- Dr. Cyrus & Myrtle Katzen Cancer Research Center
- George Washington University
- Susan G. Komen for the Cure (BCTR0707225)
- National Natural Science Foundation of China (81172049)
- Science and Technology Innovation Team of Colleges and Universities of Sichuan Province (13TD0032)
- Applied Basic Research Program of Science and Technology Department of Sichuan province (2014JC0121)
- Luzhou City special foundation (2013LZLY-J10)
This publication has 25 references indexed in Scilit:
- A positive feedback between p53 and miR-34 miRNAs mediates tumor suppressionGenes & Development, 2014
- Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancerLung Cancer, 2011
- DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancerCancer Biology & Therapy, 2011
- The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44Nature Medicine, 2011
- MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1American Journal of Physiology-Endocrinology and Metabolism, 2010
- Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancerCell Cycle, 2008
- The Biology of Cancer Stem CellsAnnual Review of Cell and Developmental Biology, 2007
- Transactivation of miR-34a by p53 Broadly Influences Gene Expression and Promotes ApoptosisMolecular Cell, 2007
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- Stem cells, cancer, and cancer stem cellsNature, 2001